ACT: The MATTERHORN trial showed a 22% reduction in the risk of death with the Imfinzi regimen. How significant is this ...

See Agentic AI in action as it eases site payments manual processes such as Clinical Trial Agreements (CTAs) ingestion and ...

Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...

In today’s ACT Brief, we spotlight how new OpenAI collaborations are transforming drug development, how AI is driving smarter site activation in global trials, and how the FDA’s approval of a ...

On October 27, Thermo Fisher Scientific and Lundbeck both announced new collaborations with OpenAI. These moves represent a continuing trend of drug development companies inking deals with technology ...

Addressing the imbalance in clinical trial workloads by empowering mid-level investigators and using AI to expand access to ...

Examining how artificial intelligence can help identify true key opinion leaders in emerging markets to improve site ...

In today’s ACT Brief, we examine how artificial intelligence is helping uncover site leaders in underserved regions to strengthen trial diversity—and explore new research suggesting Ozempic may reduce ...

Explore how Dash Solutions is transforming clinical trial payments through its dashClinical platform, improving site ...

Highlighting how technology and mindset shifts can help expand breast cancer research leadership beyond high-income countries ...

Examining how shifting leadership patterns in breast cancer research signal growing international participation—and the ...

In today’s ACT Brief, we spotlight expanding AI collaborations transforming life sciences, the role of patient-centric technology in improving global trial diversity, and the FDA’s approval of Bayer’s ...